Association of epidermal growth factor receptor and K‑Ras mutations with smoking history in non‑small cell lung cancer patients

Baykara,Onur; Tansarikaya,Merve; Demirkaya,Ahmet; Kaynak,Kamil; Tanju,Serhan; Toker,Alper; Buyru,Nur

doi:10.3892/etm.2012.829

Association of epidermal growth factor receptor and K‑Ras mutations with smoking history in non‑small cell lung cancer patients

Authors:
- Onur Baykara
- Merve Tansarikaya
- Ahmet Demirkaya
- Kamil Kaynak
- Serhan Tanju
- Alper Toker
- Nur Buyru
View Affiliations

Affiliations: Department of Medical Biology, Cerrahpasa Medical Faculty, Istanbul University, Kocamustafapasa, Istanbul 34098, Turkey, Department of Chest Diseases, Cerrahpasa Medical Faculty, Istanbul University, Kocamustafapasa, Istanbul 34098, Turkey, Department of Chest Diseases, Istanbul Medical Faculty, Istanbul University, Capa, Istanbul 34093, Turkey
Published online on: November 23, 2012 https://doi.org/10.3892/etm.2012.829
Pages: 495-498

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer, a major health problem affecting the epithelial lining of the lower respiratory tract, is considered to be one of the deadliest types of cancer in males and females and it is well‑known that smoking is the chief cause of lung cancer. In addition to smoking and environmental factors, genetic susceptibility may also contribute to the development of lung cancer. Previous studies have shown that certain non‑small cell lung cancer (NSCLC) patients harbor gain‑of‑function mutations in the epidermal growth factor receptor gene (EGFR). Phosphorylated EGFR triggers the activation of intracellular signal transduction pathways, including the RAS‑MAPK, PI3K‑Akt and STAT pathways. However, K‑Ras gene point mutations in codons 12, 13 or 61 cause the inactivation of GTPase activity which results in overstimulation of cellular growth and gives rise to neoplastic development. Our aim was to investigate the presence and association of EGFR and K‑Ras mutations in 50 primary NSCLC patients with a smoking history by using real‑time PCR and sequencing. EGFR mutations were detected in four patients (8%). Two of these mutations were L858R mutations and the remaining two were deletion mutations spanning between codons 746 and 750. The L858R mutation was significantly associated with smoking status (P=0.003). K‑Ras codon 12 and 61 mutations were also observed in four patients. However, no association was observed between K‑Ras mutations and the tumor staging, gender, histology and smoking status of the patients.

View Figures

View References

1.	Parkin DM, Bray F, Ferlay J and Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer. 94:153–156. 2001. View Article : Google Scholar : PubMed/NCBI
2.	Flehinger BJ, Kimmel M, Polyak T and Melamed MR: Screening for lung cancer. The Mayo Lung Project revisited. Cancer. 72:1573–1580. 1993. View Article : Google Scholar : PubMed/NCBI
3.	Strauss GM: Measuring effectiveness of lung cancer screening: from concensus to controversy and back. Chest. 112(Suppl 4): 216S–228S. 1997. View Article : Google Scholar : PubMed/NCBI
4.	Amos CI, Xu W and Spitz MR: Is there a genetic basis for lung cancer susceptibility? Recent Results Cancer Res. 151:3–12. 1999. View Article : Google Scholar : PubMed/NCBI
5.	Wood ME, Kelly K, Mullineaux LG and Bunn PA Jr: The inherited nature of lung cancer: a pilot study. Lung Cancer. 30:135–144. 2000. View Article : Google Scholar : PubMed/NCBI
6.	Kopreski MS, Benko FA, Borys DJ, Khan A, McGarrity TJ and Gocke CD: Somatic mutation screening: identification of individuals harboring K-Ras mutations with the use of plasma DNA. J Natl Cancer Inst. 92:918–923. 2000. View Article : Google Scholar : PubMed/NCBI
7.	Forgacs E, Zöchbauer-Müller S, Oláh E and Minna JD: Molecular genetic abnormalities in the pathogenesis of human lung cancer. Pathol Oncol Res. 7:6–13. 2001. View Article : Google Scholar : PubMed/NCBI
8.	Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T and Mitsudomi T: Mutations of the Epidermal Growth Factor Receptor gene in lung cancer: Biological and clinical implications. Cancer Res. 64:8919–8923. 2004. View Article : Google Scholar
9.	Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, Fong KM, et al: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 97:339–346. 2005. View Article : Google Scholar : PubMed/NCBI
10.	Chang JW, Liu HP, Hsieh MH, Fang YF, Hsieh MS, Hsieh JJ, Chiu YT, et al: Increased epidermal growth factor receptor (EGFR) gene copy number is strongly associated with EGFR mutations and adenocarcinoma in non-small cell lung cancers: a chromogenic in situ hybridization study of 182 patients. Lung Cancer. 61:328–339. 2008. View Article : Google Scholar : PubMed/NCBI
11.	Sasaki H, Endo K, Okuda K, Kawano O, Kitahara N, Tanaka H, Matsumura A, et al: Epidermal growth factor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer. J Cancer Res Clin Oncol. 134:569–577. 2008. View Article : Google Scholar : PubMed/NCBI
12.	Giaccone G, Gallegos Ruiz M, Le Chevalier T, Thatcher N, Smit E, Rodriguez JA, Janne P, et al: Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. Clin Cancer Res. 12:6049–6055. 2006. View Article : Google Scholar : PubMed/NCBI
13.	Bos JL: ras oncogenes in human cancer: a review. Cancer Res. 49:4682–4689. 1989.PubMed/NCBI
14.	Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, Veronese S, Siena S and Bardelli A: Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res. 67:2643–2648. 2007. View Article : Google Scholar
15.	Oldenhuis CN, Oosting SF, Gietema JA and de Vries EG: Prognostic versus predictive value of biomarkers in oncology. Eur J Cancer. 44:946–53. 2008. View Article : Google Scholar : PubMed/NCBI
16.	Linardou H, Dahabreh IJ, Kanaloupiti D, Siannis F, Bafaloukos D, Kosmidis P, Papadimitriou CA and Murray S: Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol. 9:962–972. 2008. View Article : Google Scholar : PubMed/NCBI
17.	Sasaki H, Shimizu S, Okuda K, Kawano O, Yukiue H, Yano M and Fujii Y: Epidermal growth factor receptor gene amplification in surgical resected Japanese lung cancer. Lung Cancer. 64:295–300. 2009. View Article : Google Scholar : PubMed/NCBI
18.	Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, Zakowski MF, et al: KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2:e172005. View Article : Google Scholar : PubMed/NCBI
19.	Hemming AW, Davis NL, Kluftinger A, Robinson B, Quenville NF, Liseman B and LeRiche J: Prognostic markers of colorectal cancer: an evaluation of DNA content, epidermal growth factor receptor, and Ki-67. J Surg Oncol. 51:147–152. 1992. View Article : Google Scholar : PubMed/NCBI
20.	Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, et al: EGF receptor gene mutations are common in lung cancers from ‘never smokers’ and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 101:13306–13311. 2004.
21.	Rusch V, Baselga J, Cordon-Cardo C, Orazem J, Zaman M, Hoda S, McIntosh J, et al: Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res. 53(Suppl 10): 2379–2385. 1993.PubMed/NCBI
22.	Ciardiello F and Tortora G: EGFR antagonists in cancer treatment. N Engl J Med. 358:1160–1174. 2008. View Article : Google Scholar : PubMed/NCBI
23.	Le Calvez F, Mukeria A, Hunt JD, Kelm O, Hung RJ, Tanière P, Brennan P, Boffetta P, et al: TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers. Cancer Res. 65:5076–5083. 2005.PubMed/NCBI
24.	Tam IY, Chung LP, Suen WS, Wang E, Wong MC, Ho KK, Lam WK, et al: Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin Cancer Res. 12:1647–1653. 2006. View Article : Google Scholar : PubMed/NCBI
25.	Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
26.	Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI
27.	Sugio K, Uramoto H, Ono K, Oyama T, Hanagiri T, Sugaya M, Ichiki M, et al: Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking. Br J Cancer. 94:896–903. 2006. View Article : Google Scholar : PubMed/NCBI
28.	Tokumo M, Toyooka S, Kiura K, Shigematsu H, Tomii K, Aoe M, Ichimura K, et al: The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res. 11:1167–1173. 2005.PubMed/NCBI
29.	Pham D, Kris MG, Riely GJ, Sarkaria IS, McDonough T, Chuai S, Venkatraman ES, et al: Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. J Clin Oncol. 24:1700–1704. 2006. View Article : Google Scholar : PubMed/NCBI
30.	Lee YJ, Shim HS, Kang YA, Hong SJ, Kim HK, Kim H, Kim SK, et al: Dose effect of cigarette smoking on frequency and spectrum of epidermal growth factor receptor gene mutations in Korean patients with non-small cell lung cancer. J Cancer Res Clin Oncol. 136:1937–1944. 2010. View Article : Google Scholar : PubMed/NCBI
31.	Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S, et al: Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol. 23:2513–2520. 2005. View Article : Google Scholar
32.	Samowitz WS, Curtin K, Schaffer D, Robertson M, Leppert M and Slattery ML: Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. Cancer Epidemiol Biomarkers Prev. 9:1193–1197. 2000.PubMed/NCBI
33.	Keller JW, Franklin JL, Graves-Deal R, Friedman DB, Whitwell CW and Coffey RJ: Oncogenic KRAS provides a uniquely powerful and variable oncogenic contribution among RAS family members in the colonic epithelium. J Cell Physiol. 210:740–749. 2007. View Article : Google Scholar : PubMed/NCBI
34.	Wang JY, Wang YH, Jao SW, Lu CY, Kuo CH, Hu HM, Hsieh JS, et al: Molecular mechanisms underlying the tumorigenesis of colorectal adenomas: correlation to activated K-Ras oncogene. Oncol Rep. 16:1245–1252. 2006.PubMed/NCBI
35.	Pfeifer GP, Denissenko MF, Olivier M, Tretyakova N, Hecht SS and Hainaut P: Tobacco smoke carcinogenesis, DNA damage and p53 mutations in smoking-associated cancers. Oncogene. 21:7435–7451. 2002. View Article : Google Scholar : PubMed/NCBI
36.	Pines G, Köstler WJ and Yarden Y: Oncogenic mutant forms of EGFR: lessons in signal transduction and targets for cancer therapy. FEBS Lett. 584:2699–2706. 2010. View Article : Google Scholar : PubMed/NCBI
37.	Schmid K, Oehl N, Wrba F, Pirker R, Pirker C and Filipits M: EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. Clin Cancer Res. 15:4554–4560. 2009. View Article : Google Scholar : PubMed/NCBI
38.	Han SW, Kim TY, Jeon YK, Hwang PG, Im SA, Lee KH, Kim JH, et al: Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-Ras mutation, and Akt phosphorylation. Clin Cancer Res. 12:2538–2544. 2006. View Article : Google Scholar : PubMed/NCBI
39.	van Zandwijk N, Mathy A, Boerrigter L, Ruijter H, Tielen I, de Jong D, Baas P, et al: EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer. Ann Oncol. 18:99–103. 2007.PubMed/NCBI
40.	Massarelli E, Varella-Garcia M, Tang X, Xavier AC, Ozburn NC, Liu DD, Bekele BN, et al: KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res. 13:2890–2896. 2007. View Article : Google Scholar : PubMed/NCBI
41.	Yamanaka S, Gu Z, Sato M, Fujisaki R, Inomata K, Sakurada A, Inoue A, et al: siRNA targeting against EGFR, a promising candidate for a novel therapeutic application to lung adenocarcinoma. Pathobiology. 75:2–8. 2008. View Article : Google Scholar : PubMed/NCBI